Last updated on January 2019

Low-dose Radiotherapy Plus Chemotherapy With GemOx and Stereotactic Radiotherapy for Advanced Pancreatic Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pancreatic Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Pathologically confirmed adenocarcinoma of the pancreas
  • Patients with unresectable disease based on institutional standardized criteria of unresectability or patients whose disease appeared potentially resectable on axial CT imaging but were found unresectable at surgery
  • Eastern Cooperative Oncology Group (ECOG) performance status 2. Age 18
  • Patients with biliary or gastroduodenal obstruction must have drainage or surgical bypass prior to starting treatment
  • Patients with radiographically assessable disease
  • Adequate bone marrow, hepatic and renal function: -Hemoglobin >10.0 g/dL, absolute neutrophil count > 1.5 x 10^9/L, platelet count > 100 x 10^9/L. -Aspartate transaminase (AST or SGOT) and alanine transaminase (ALT or SGPT) should be 3 x upper limit of normal (ULN). -Total bilirubin < 2 mg/dL. Patients with elevated bilirubin due to obstruction should be stented and their bilirubin should decrease to < 2 mg/dL prior to study entry. - Creatinine < 3 mg/dL or Creatinine clearance > 40 mL/min (calculated according to Cockroft and Gault)

Exclusion Criteria:

  • Evidence of metastatic disease in the major viscera or peritoneal seeding or ascites
  • Gastric or duodenal obstruction
  • Previous peripheral neuropathy
  • Previous irradiation to the planned field; previous chemotherapy for pancreatic cancer
  • Malignancy (within the past two years) except non-melanomatous skin cancer or carcinoma in situ of the cervix, uterus, or bladder

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.